Cargando…

MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR

BACKGROUND: Triple-negative breast cancer (TNBC) is highly aggressive with an increased metastatic incidence compared to other breast cancer subtypes. However, due to the absence of clinically reliable biomarkers and targeted therapy in TNBC, outcomes are suboptimal. Hence, there is an urgent need t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhary, Sanjib, Appadurai, Muthamil Iniyan, Maurya, Shailendra Kumar, Nallasamy, Palanisamy, Marimuthu, Saravanakumar, Shah, Ashu, Atri, Pranita, Ramakanth, Chirravuri Venkata, Lele, Subodh M., Seshacharyulu, Parthasarathy, Ponnusamy, Moorthy P., Nasser, Mohd W., Ganti, Apar Kishor, Batra, Surinder K., Lakshmanan, Imayavaramban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012760/
https://www.ncbi.nlm.nih.gov/pubmed/36918912
http://dx.doi.org/10.1186/s13058-023-01630-7
_version_ 1784906671972155392
author Chaudhary, Sanjib
Appadurai, Muthamil Iniyan
Maurya, Shailendra Kumar
Nallasamy, Palanisamy
Marimuthu, Saravanakumar
Shah, Ashu
Atri, Pranita
Ramakanth, Chirravuri Venkata
Lele, Subodh M.
Seshacharyulu, Parthasarathy
Ponnusamy, Moorthy P.
Nasser, Mohd W.
Ganti, Apar Kishor
Batra, Surinder K.
Lakshmanan, Imayavaramban
author_facet Chaudhary, Sanjib
Appadurai, Muthamil Iniyan
Maurya, Shailendra Kumar
Nallasamy, Palanisamy
Marimuthu, Saravanakumar
Shah, Ashu
Atri, Pranita
Ramakanth, Chirravuri Venkata
Lele, Subodh M.
Seshacharyulu, Parthasarathy
Ponnusamy, Moorthy P.
Nasser, Mohd W.
Ganti, Apar Kishor
Batra, Surinder K.
Lakshmanan, Imayavaramban
author_sort Chaudhary, Sanjib
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) is highly aggressive with an increased metastatic incidence compared to other breast cancer subtypes. However, due to the absence of clinically reliable biomarkers and targeted therapy in TNBC, outcomes are suboptimal. Hence, there is an urgent need to understand biological mechanisms that lead to identifying novel therapeutic targets for managing metastatic TNBC. METHODS: The clinical significance of MUC16 and ELAVL1 or Hu antigen R (HuR) was examined using breast cancer TCGA data. Microarray was performed on MUC16 knockdown and scramble TNBC cells and MUC16-associated genes were identified using RNA immunoprecipitation and metastatic cDNA array. Metastatic properties of MUC16 were evaluated using tail vein experiment. MUC16 and HuR downstream pathways were confirmed by ectopic overexpression of MUC16-carboxyl-terminal (MUC16-Cter), HuR and cMyc as well as HuR inhibitors (MS-444 and CMLD-2) in TNBC cells. RESULTS: MUC16 was highly expressed in TNBC and correlated with its target HuR. Depletion of MUC16 showed decreased invasion, migration, and colony formation abilities of human and mouse TNBC cells. Mice injected with MUC16 depleted cells were less likely to develop lung metastasis (P = 0.001). Notably, MUC16 and HuR were highly expressed in the lung tropic TNBC cells and lung metastases. Mechanistically, we identified cMyc as a HuR target in TNBC using RNA immunoprecipitation and metastatic cDNA array. Furthermore, MUC16 knockdown and pharmacological inhibition of HuR (MS-444 and CMLD-2) in TNBC cells showed a reduction in cMyc expression. MUC16-Cter or HuR overexpression models indicated MUC16/HuR/cMyc axis in TNBC cell migration. CONCLUSIONS: Our study identified MUC16 as a TNBC lung metastasis promoter that acts through HuR/cMyc axis. This study will form the basis of future studies to evaluate the targeting of both MUC16 and HuR in TNBC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-023-01630-7.
format Online
Article
Text
id pubmed-10012760
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100127602023-03-15 MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR Chaudhary, Sanjib Appadurai, Muthamil Iniyan Maurya, Shailendra Kumar Nallasamy, Palanisamy Marimuthu, Saravanakumar Shah, Ashu Atri, Pranita Ramakanth, Chirravuri Venkata Lele, Subodh M. Seshacharyulu, Parthasarathy Ponnusamy, Moorthy P. Nasser, Mohd W. Ganti, Apar Kishor Batra, Surinder K. Lakshmanan, Imayavaramban Breast Cancer Res Research BACKGROUND: Triple-negative breast cancer (TNBC) is highly aggressive with an increased metastatic incidence compared to other breast cancer subtypes. However, due to the absence of clinically reliable biomarkers and targeted therapy in TNBC, outcomes are suboptimal. Hence, there is an urgent need to understand biological mechanisms that lead to identifying novel therapeutic targets for managing metastatic TNBC. METHODS: The clinical significance of MUC16 and ELAVL1 or Hu antigen R (HuR) was examined using breast cancer TCGA data. Microarray was performed on MUC16 knockdown and scramble TNBC cells and MUC16-associated genes were identified using RNA immunoprecipitation and metastatic cDNA array. Metastatic properties of MUC16 were evaluated using tail vein experiment. MUC16 and HuR downstream pathways were confirmed by ectopic overexpression of MUC16-carboxyl-terminal (MUC16-Cter), HuR and cMyc as well as HuR inhibitors (MS-444 and CMLD-2) in TNBC cells. RESULTS: MUC16 was highly expressed in TNBC and correlated with its target HuR. Depletion of MUC16 showed decreased invasion, migration, and colony formation abilities of human and mouse TNBC cells. Mice injected with MUC16 depleted cells were less likely to develop lung metastasis (P = 0.001). Notably, MUC16 and HuR were highly expressed in the lung tropic TNBC cells and lung metastases. Mechanistically, we identified cMyc as a HuR target in TNBC using RNA immunoprecipitation and metastatic cDNA array. Furthermore, MUC16 knockdown and pharmacological inhibition of HuR (MS-444 and CMLD-2) in TNBC cells showed a reduction in cMyc expression. MUC16-Cter or HuR overexpression models indicated MUC16/HuR/cMyc axis in TNBC cell migration. CONCLUSIONS: Our study identified MUC16 as a TNBC lung metastasis promoter that acts through HuR/cMyc axis. This study will form the basis of future studies to evaluate the targeting of both MUC16 and HuR in TNBC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-023-01630-7. BioMed Central 2023-03-14 2023 /pmc/articles/PMC10012760/ /pubmed/36918912 http://dx.doi.org/10.1186/s13058-023-01630-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chaudhary, Sanjib
Appadurai, Muthamil Iniyan
Maurya, Shailendra Kumar
Nallasamy, Palanisamy
Marimuthu, Saravanakumar
Shah, Ashu
Atri, Pranita
Ramakanth, Chirravuri Venkata
Lele, Subodh M.
Seshacharyulu, Parthasarathy
Ponnusamy, Moorthy P.
Nasser, Mohd W.
Ganti, Apar Kishor
Batra, Surinder K.
Lakshmanan, Imayavaramban
MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
title MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
title_full MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
title_fullStr MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
title_full_unstemmed MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
title_short MUC16 promotes triple-negative breast cancer lung metastasis by modulating RNA-binding protein ELAVL1/HUR
title_sort muc16 promotes triple-negative breast cancer lung metastasis by modulating rna-binding protein elavl1/hur
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012760/
https://www.ncbi.nlm.nih.gov/pubmed/36918912
http://dx.doi.org/10.1186/s13058-023-01630-7
work_keys_str_mv AT chaudharysanjib muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT appaduraimuthamiliniyan muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT mauryashailendrakumar muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT nallasamypalanisamy muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT marimuthusaravanakumar muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT shahashu muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT atripranita muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT ramakanthchirravurivenkata muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT lelesubodhm muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT seshacharyuluparthasarathy muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT ponnusamymoorthyp muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT nassermohdw muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT gantiaparkishor muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT batrasurinderk muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur
AT lakshmananimayavaramban muc16promotestriplenegativebreastcancerlungmetastasisbymodulatingrnabindingproteinelavl1hur